Skandinaviska Enskilda Banken (SEB)
BPMC

Skandinaviska Enskilda Banken (SEB)’s Blueprint Medicines BPMC Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,500
Closed -$1.47M – 806
2025
Q2 		$1.47M Buy
+11,500
New +$1.19M 0.01% 617

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s BPMC Position: Q3 2025 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 11,500 shares — an estimated $1.47M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in BPMC in Q2 2025 and held it in 1 quarter. The position peaked at $1.47M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 11,500 Blueprint Medicines shares in Q3 2025, an estimated $1.47M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Blueprint Medicines in Q2 2025 and held it in 1 quarter.
  • Skandinaviska Enskilda Banken (SEB)'s Blueprint Medicines position peaked at $1.47M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q3 2025, filed 7 Nov 2025.